The "Hemophilia Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Hemophilia market is expected to witness a CAGR of 5.9% during the forecast period (2021-2026).
Key Market Trends
Hemophilia A is Expected to Hold Significant Market Share in the Disease Type Segment
Hemophilia A is the most common severe bleeding disorder. Replacement therapy, providing the missing coagulation factor, has been the mainstay of treatment both prophylactically and to treat bleeding. According to the data published by the World Federation of Hemophilia in 2019, hemophilia is more recorded among males, and approximately 24.6 in 100.000 neonates suffer from hemophilia A.
This is a rare genetic bleeding disorder projected that affected around 157,517 people worldwide in 2019. The key medication to treat hemophilia A is concentrated FVIII product, also known as clotting factor. The recombinant factor products that are developed in a laboratory using DNA technology impede the use of human-derived pools of donor-sourced plasma. Due to the advances in recombinant protein engineering and the introduction of gene therapy and novel strategies to target the coagulation cascade.
North America Dominates the Market and Expected to do Same in the Forecast Period
The North America region dominates the global market. The major factors driving the growth of the hemophilia market in the region include the therapeutic advances in hemophilia, which led to a wave of new FDA-approved agents and increasing awareness about technologically advanced products, increasing prevalence hemophilia, and the presence of a huge patient pool. The United States is the largest market in the region.
According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation). In the United States, agencies, like hemophilia Association of America, generally offers continuous treatment for patients by introducing different co-pay initiatives. This is further expected to balance the expenditures for patients and assist them in providing access to new products. In the United States, the BioMarin company is conducting Phase III clinical trial with valoctocogene roxaparvovec (BMN 270) to assess the efficacy of BMN 270 in the treatment of hemophilia A.
Therefore, advancements in the gene therapy and novel strategies to target the coagulation factors is expected to drive the market in the near future. In the United States, Genzyme Corporation offers "ALPROLIX" (Coagulation Factor IX (Recombinant), Fc Fusion Protein), an injectable medicine used to help control and prevent bleeding in people with hemophilia B. Thus, the increasing research and development in the development of new effective therapies, along with the rising prevalence of hemophilia in the United States, is expected to drive the market over the forecast period.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Hemophilia
4.2.2 Favorable Government Initiatives
4.2.3 Rising R&D and New Product Development
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Lack of Awareness Regarding Advanced Technologies
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Disease Type
5.2 By Therapy
5.3 By Product Type
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/hvga64
These press releases may also interest you